arrow_back Search

EFTA02018266

DOJ Epstein Files
folder Dataset 10 insert_drive_file EFTA02018266.pdf description PDF text_fields 294 words · 2.0k chars
open_in_new View original source

To: .eevacation maii.conjeevacation@gmaii.comi: .11jeevacationgogmall.com1 From: Sent un 1 /21/2012 3:31:09 PM Subject: Re: Aaah thank you Sent from my iPhone On Oct 21, 2012, at 11:20 AM, J ieevacation@gmail.com> wrote: Wrap in bread Sent from my iPad On Oct 21, 2012, at 10:59 AMS wrote: Thank you, I have also researched. I am on the 60. I will try cutting one in half so that it will equal 90. It is a capsule with powder in that bums but I will try. Sent from my iPhone On Oct 21, 2012, at 7:14 AM, Jeffrey Epstein <jecvacation@gmail.com> wrote: you are on the lowest recomment dose not the highest. if you are taking 30„ s take one additional this week to start if not try cutting a 60 in half and add Generalized Anxiety Disorder — It is generally agreed that episodes of generalized anxiety disorder require several months or longer of sustained pharmacological therapy. Maintenance of efficacy in GAD was demonstrated with Cymbalta as monotherapy. Cymbalta should be administered in a dose range of 60-120 mg once daily. Patients should be periodically reassessed to determine the continued need for maintenance treatment and the appropriate dose for such treatment [see Clinical Studies ( JA,2)]. *********************************************************** The information contained in this communication is EFTA_R1_00522148 EFTA02018266 confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of Jeffrey Epstein Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to jeevacation@amail.com, and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved EFTA_R1_00522149 EFTA02018267